Journal article icon

Journal article

Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.

Abstract:

Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. We sought to determine the relationships between: (a) trait hope, expectation of symptom benefit from chemotherapy, and anxiety and depression; (b) hope and perceived efficacy of chemotherapy; and (c) unfulfilled hope (where expectations for benefit are not fulfilled) and depression. Methods. Adult patients enrolled within stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study were i...

Expand abstract

Actions


Access Document


Authors


Sjoquist, KM More by this author
Friedlander, ML More by this author
O'Connell, RL More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Primary Care Health Sciences
Expand authors...
Journal:
The oncologist
Volume:
18
Issue:
11
Pages:
1221-1228
Publication date:
2013
DOI:
EISSN:
1549-490X
ISSN:
1083-7159
URN:
uuid:6cebe753-2bb2-42e3-90f5-31a8fc9f3c5a
Source identifiers:
435035
Local pid:
pubs:435035

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP